Investing in the OTCQB Venture Market offers a unique landscape of opportunities for investors, particularly those who value transparency and the potential for discovering promising ventures. This article sheds light on the OTCQB Venture Market Watchlist, where we explore the importance of transparency for investors seeking to navigate the world of small and developing companies. Join us as we uncover the principles and benefits of this market segment, designed to provide a clear, well-informed path for those looking to invest wisely and uncover potential gems in the world of stocks.
--
Wolf Energy Services Inc. (OTCQB: WOEN) - Wolf Energy Services Inc., a Florida corporation, operates through its wholly-owned subsidiary, Banner Midstream Corp., a Delaware corporation established in 2018. Banner offers two core services: (1) the provision of frac sand transportation and logistics support to major hydraulic fracturing and drilling operations, facilitated by its wholly-owned subsidiary, Pinnacle Frac Transport LLC; and (2) the procurement and financial assistance of equipment for oilfield transportation service contractors, managed through its wholly-owned subsidiary, Capstone Equipment Leasing LLC. Our last update from the company dates back to the beginning of this year when they announced a forward stock split and a company rebrand. For an abridged overview, we've extracted details from their recent filings. On September 7, 2022, Banner Midstream Corp executed a reverse merger with Wolf Energy Services Inc., previously known as Enviro Technologies U.S., Inc. In this merger, BitNile Metaverse, Inc., the parent of Banner Midstream, received 51,987,832 shares of Wolf Energy Services Inc. common stock in exchange for the entirety of Banner's capital stock owned by BitNile Metaverse, effectively representing 100% of Banner's outstanding shares at the time of the reverse merger. In April this year, the company's share price reached above $0.04, but it has since dipped to nearly $0.01. Given the limited number of shares available, we will keep a watchful eye for any increased trading activity or news releases from the company.
--
Adhera Therapeutics Inc. (OTCQB: ATRX) - Adhera Therapeutics is a clinical-stage biopharmaceutical company focused on fast-tracking advanced drug candidates. They have two key candidates: MLR-1019 (armesocarb) for Parkinson's Disease and MLR-1023 (tolimidone) for Type I Diabetes, Non-Alcoholic Steatohepatitis (NASH), and pulmonary inflammation conditions. MLR-1023, a lyn kinase activator, has demonstrated exceptional safety in over 700 patients. MLR-1019 uniquely addresses both movement and non-movement symptoms of Parkinson's Disease. The company is actively progressing both candidates through Phase 2 clinical trials and exploring additional drug development opportunities while maintaining legacy assets, including CEQ508, aimed at suppressing polyps in Familial Adenomatous Polyposis (FAP). Our last update from the company was at the beginning of the year when they announced a dose-finding study of MLR-1023 (tolimidone) for Type 1 Diabetes in collaboration with the Alberta Diabetes Institute at the University of Alberta in Canada. The company is finalizing trial details, which will be released soon and used to optimize dosing for an upcoming Phase 2 clinical trial of MLR-1023. Additionally, the company is actively working towards uplisting to NASDAQ to enhance liquidity and secure financing for clinical trials. The share price has seen a significant decline from over $0.14 in the summer to $0.014 in recent months. We'll continue to monitor for updates.
--
Endexx Corp. (OTCQB: EDXC) - Endexx Corporation creates and markets plant-based wellness and skincare products, including balms, creams, lotions, butters, masks, scrubs, and oils. These products are meticulously developed using a decade of clinical research and laboratory work to ensure they deliver effective and skin-friendly formulations for optimal skin health and grooming wellness. This month, the company announced a $400,000 reorder for its HYLA vape product, including the existing DOPA 1200 puff device and the new 4500 puff device. The 4500 device is pending final permits for Italy and is expected to be shipped in the first fiscal quarter of 2024. This reorder highlights the strengthening of distributor relationships and a rising global demand for HYLA products. The company also recently filed an amended and consolidated audited 10-Q/A Quarterly report for the quarter ending March 31, 2023. Todd Davis, the company's CEO, expressed optimism about their growth and expansion in the cannabis and hemp industry, both domestically and globally, particularly in the first half of Fiscal 2023. We'll continue to monitor the company for updates and any potential rebound in its stock price, aiming for a return to the $0.05 range.
--
Cannabis Sativa, Inc. (OTCQB: CBDS) - Cannabis Sativa, Inc. (CBDS) is involved in telehealth, licensing cannabis-related intellectual property, branding for cannabis products and services, technology services, and related business activities. They possess U.S. patents for the Ecuadorian Sativa strain of Cannabis and a marijuana lozenge, along with proprietary compositions for treating hypertensive disorders. Additionally, they operate the subsidiary PrestoDoctor®. Our last company update was in April this year when PrestoDoctor offered on-site evaluations at the 9th annual Pennsylvania Cannabis Festival, Pocono 420, at the Pocono Raceway in Long Pond, Pennsylvania. COO Rob Tankson mentioned that festival attendees could swiftly complete their medical evaluation, utilizing their proprietary technology while ensuring privacy. PrestoDoctor has conducted over 100 in-person events. We'll be closely monitoring the company's performance since its share price has dipped to low sub-penny levels from over $0.03 last month. Additionally, the company entered into a Merger Agreement with MJ Harvest, Inc. (MJHI) in the summer of 2022. We'll be watching for MJHI to provide updates and see if the merger is still progressing.
--
Omnitek Engineering Corp. (OTCQB: OMTK) - Omnitek Engineering Corp. creates and markets exclusive diesel-to-natural gas conversion systems and related products. They offer innovative and cost-effective alternative energy and emissions control solutions, including new natural gas engines employing their technology for global customers. The company's most recent press release dates back to early 2021 when they announced EURO VI Phase-E certification for their OT13 heavy-duty natural gas engine. Werner Funk, the President and CEO of Omnitek Engineering Corp, expressed optimism about the competitively priced EURO VI Phase-E engine, anticipating strong demand. The achievement was attributed to extensive engine development and the integration of Omnitek's patented natural gas engine management system components along with an efficient catalytic converter. We'll be monitoring for updates or increased trading activity since the share price has fallen from over $0.04 in March to just above a penny
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. We have been retained by a third party, Mt Zion Ventures, to assist in the production and distribution of content related to Endexx Corp. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTime Penny is not a fiduciary by virtue of any person's use of or access to this content.
Adhera Therapeutics, Inc. is a specialty biotech company. The Company is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The Company's advanced development programs are MLR-1019, a small molecule drug candidate being developed for PD, and MLR-1023, being developed to treat Type 1 diabetes. MLR-1019 is a highly selective dopamine re-uptake inhibitor for treating the dyskinesias associated with chronic dopamine precursor levodopa (L-DOPA) treatment in PD patients. MLR-1019 is a highly selective dopamine reuptake transporter (DAT) inhibitor used for the treatment of type 1 diabetes, non-alcoholic steatohepatitis, and pulmonary inflammation. It utilizes a virtual drug development model, where contract research organizations (CROs) are employed to undertake certain drug discovery and development services on the Companyâs behalf and under its direct supervision.
ADHERA THERAPEUTICS, INC. 
